{"filing":{"accession_number":"0001213900-26-102810","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"ea0306377-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026102810/ea0306377-6k_scisparc.htm"},"events":[{"id":34708,"run_id":31953,"accession_number":"0001213900-26-102810","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with NeuroThera's PEA technology, developed through an ongoing collaboration with Clearmind Medicine. The disclosure highlights expansion of the intellectual property portfolio for potential therapeutic applications in mental health and substance use disorders. This is a material operational/strategic milestone—the maturation and enhancement of a core asset (patent portfolio) supporting the company's drug development programs—but does not fit the specific event categories of M\u0026A, earnings, executive changes, or other named types. It represents progress in the company's clinical-stage pharmaceutical development strategy.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-09-24","form":"6-K","submitted_at":null,"items":[{"id":38528,"accession_number":"0001213900-26-102810","item_number":"EX-99.1","item_title":"ea030637702ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with NeuroThera's PEA technology, developed through an ongoing collaboration with Clearmind Medicine. The disclosure highlights expansion of the intellectual property portfolio for potential therapeutic applications in mental health and substance use disorders. This is a material operational/strategic milestone—the maturation and enhancement of a core asset (patent portfolio) supporting the company's drug development programs—but does not fit the specific event categories of M\u0026A, earnings, executive changes, or other named types. It represents progress in the company's clinical-stage pharmaceutical development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:27:38.526293+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38528,"accession_number":"0001213900-26-102810","item_number":"EX-99.1","item_title":"ea030637702ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces the publication of three U.S. patent applications covering novel combinations of LSD, ketamine, and ibogaine with NeuroThera's PEA technology, developed through an ongoing collaboration with Clearmind Medicine. The disclosure highlights expansion of the intellectual property portfolio for potential therapeutic applications in mental health and substance use disorders. This is a material operational/strategic milestone—the maturation and enhancement of a core asset (patent portfolio) supporting the company's drug development programs—but does not fit the specific event categories of M\u0026A, earnings, executive changes, or other named types. It represents progress in the company's clinical-stage pharmaceutical development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:27:38.526293+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-09-24"}]}